MorphoSys AG
XETRA:MOR
MorphoSys AG
Cash from Financing Activities
MorphoSys AG
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MorphoSys AG
XETRA:MOR
|
Cash from Financing Activities
€43m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-11%
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash from Financing Activities
-€778.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Cash from Financing Activities
€230.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Cash from Financing Activities
€84.5m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Cash from Financing Activities
-€6.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
Formycon AG
XETRA:FYB
|
Cash from Financing Activities
€40.7m
|
CAGR 3-Years
33%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
See Also
What is MorphoSys AG's Cash from Financing Activities?
Cash from Financing Activities
43m
EUR
Based on the financial report for Dec 31, 2023, MorphoSys AG's Cash from Financing Activities amounts to 43m EUR.
What is MorphoSys AG's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-11%
Over the last year, the Cash from Financing Activities growth was -86%. The average annual Cash from Financing Activities growth rates for MorphoSys AG have been -64% over the past three years , -25% over the past five years , and -11% over the past ten years .